Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 11/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.52 |
| ▸ | F2R | P25116 | 7/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19359643 | 1.00 | NAAA (0.56) | NAAAEPHX1ITGB3ITGA2BF2R | |
| SCHEMBL3199790 | 1.00 | NAAA (0.56) | NAAAEPHX1ITGB3ITGA2BF2R | |
| SCHEMBL5901310 | 1.00 | NAAA (0.56) | NAAAEPHX1ITGB3ITGA2BF2R | |
| SCHEMBL3199095 | 0.98 | NAAA (0.53) | NAAAEPHX1ITGB3ITGA2BF2R | |
| SCHEMBL2678008 | 0.89 | NAAA (0.62) | NAAAEPHX1ITGB3ITGA2BF2R | |
| SCHEMBL6502279 | 0.89 | NAAA (0.62) | NAAAEPHX1ITGB3ITGA2BF2R | |
| SCHEMBL9831302 | 0.88 | ALDH1A1 (0.48) | NAAAEPHX1ITGB3ITGA2BF2R | |
| SCHEMBL22139787 | 0.87 | NAAA (0.44) | NAAAEPHX1ITGB3ITGA2BF2R | |
| SCHEMBL9829575 | 0.87 | NAAA (0.65) | NAAAEPHX1ITGB3ITGA2BF2R | |
| SCHEMBL5902012 | 0.86 | NAAA (0.59) | NAAAEPHX1ITGB3ITGA2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | NAAA 177/4885EPHX1 3301/4885ITGB3 4773/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | NAAA 76/4885EPHX1 3879/4885ITGB3 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.